

<u>2008/2009 BIOTECHNOLOGY RESEARCH REVIEW</u> .....	1
<u>FOREWORD</u> .....	1
<u>CHAPTER ONE: SYNTHETIC BIOLOGY: EMERGING GLOBAL</u>	
<u>MARKETS (BIO066A)</u> .....	2
<u>INTRODUCTION</u> .....	2
<u>STUDY GOALS AND OBJECTIVES</u> .....	2
<u>REASONS FOR DOING THE STUDY</u> .....	2
<u>INTENDED AUDIENCE</u> .....	3
<u>SCOPE OF REPORT</u> .....	3
<u>METHODOLOGY</u> .....	4
<u>INFORMATION SOURCES</u> .....	4
<u>RELATED BCC REPORTS</u> .....	4
<u>ANALYST CREDENTIALS</u> .....	5
<u>SUMMARY</u> .....	5
<u>TABLE 1 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY</u>	
<u>INDUSTRY, THROUGH 2013 (\$ MILLIONS)</u> .....	6
<u>FIGURE 1 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY</u>	
<u>INDUSTRY, 2006-2013 (\$ MILLIONS)</u> .....	6
<u>OVERVIEW</u> .....	7
<u>SYNTHETIC BIOLOGY TECHNOLOGIES COVERED IN THIS</u>	
<u>REPORT</u> .....	7
<u>TABLE 2 SCOPE OF THIS REPORT</u> .....	8
<u>WHAT IS SYNTHETIC BIOLOGY?</u> .....	8
<u>WHAT IS SYNTHETIC BIOLOGY (CONTINUED)</u> .....	8
<u>DEVELOPMENT STAGE OF SYNTHETIC BIOLOGY</u> .....	9
<u>FORCES DRIVING SYNTHETIC BIOLOGY MARKET</u>	
<u>GROWTH</u> .....	10
<u>TABLE 3 SYNTHETIC BIOLOGY GROWTH DRIVING FORCES</u> .....	10
<u>Forces Driving Synthetic Biology ... (Continued)</u> .....	11
<u>GLOBAL MARKET POTENTIAL FOR SYNTHETIC BIOLOGY</u>	
<u>PRODUCTS</u> .....	12
<u>TABLE 4 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY</u>	
<u>END USER, THROUGH 2013 (\$ MILLIONS)</u> .....	12
<u>TABLE 5 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED</u>	
<u>ENERGY MARKET BY FUEL TYPE, THROUGH 2013 (\$ MILLIONS)</u> .....	13
<u>LIFE CYCLE STATUS OF SYNTHETIC BIOLOGY</u>	
<u>TECHNOLOGIES</u> .....	13
<u>TABLE 6 SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY</u>	
<u>LIFE CYCLE STAGE</u> .....	14
<u>THE SYNTHETIC BIOLOGY INDUSTRY</u> .....	14
<u>TABLE 7 SYNTHETIC BIOLOGY KEY COMPETITORS BY MARKET</u>	
<u>FOCUS</u> .....	15
<u>The Synthetic Biology Industry (Continued)</u> .....	16

<u>CHAPTER TWO: COMMERCIAL AMINO ACIDS (BIO007H)</u> .....	17
<u>INTRODUCTION</u> .....	17
<u>STUDY OBJECTIVES</u> .....	17
<u>REASONS FOR DOING THIS STUDY</u> .....	17
<u>INTENDED AUDIENCE</u> .....	17
<u>SCOPE OF REPORT</u> .....	18
<u>INFORMATION SOURCES</u> .....	18
<u>ANALYST CREDENTIALS</u> .....	19
<u>RELATED BCC REPORTS</u> .....	19
<u>BCC ON-LINE SERVICES</u> .....	19
<u>DISCLAIMER</u> .....	20
<u>SUMMARY</u> .....	20
<u>SUMMARY (CONTINUED)</u> .....	21
<u>TABLE 8 U.S. AMINO ACIDS MARKET SIZE, THROUGH 2013 (\$</u> <u>MILLIONS)</u> .....	22
<u>FIGURE 2 U.S. AMINO ACIDS MARKET SIZE, 2005-2013 (\$</u> <u>MILLIONS)</u> .....	23
<u>OVERVIEW OF AMINO ACIDS</u> .....	23
<u>TABLE 9 THE PROTEIN AMINO ACIDS</u> .....	24
<u>COMMERCIAL INTERESTS</u> .....	24
<u>TABLE 10 MAJOR COMMERCIAL APPLICATIONS</u> .....	24
<u>TABLE 10 (CONTINUED)</u> .....	25
<u>Feed Fortification</u> .....	25
<u>Food Flavoring Agents</u> .....	26
<u>Specialty Uses</u> .....	26
<u>Dietary Needs</u> .....	26
<u>TABLE 11 THE "ESSENTIAL" AMINO ACIDS</u> .....	26
<u>BIOLOGIC VALUE OF AMINO ACID MIXTURES</u> .....	27
<u>TABLE 12 PROTEIN VALUE OF SELECTED FOODS</u> .....	27
<u>RECOMMENDED DAILY ALLOWANCE</u> .....	28
<u>Amino Acid Metabolism</u> .....	28
<u>PROPERTIES</u> .....	29
<u>CHEMICAL STRUCTURE</u> .....	29
<u>TABLE 13 CHEMICAL STRUCTURE OF AMINO ACIDS</u> .....	29
<u>TABLE 13 (CONTINUED)</u> .....	30
<u>ISOLATION/ANALYSIS</u> .....	30
<u>Microbiological Assay</u> .....	30
<u>Chromatographic Separation</u> .....	30
<u>PRODUCTION TECHNOLOGY</u> .....	31
<u>TABLE 14 AMINO ACIDS BY PRODUCTION METHODS</u> .....	31
<u>Extraction</u> .....	32
<u>Fermentation</u> .....	32
<u>Microbiological Processes</u> .....	33
<u>TABLE 15 AMINO ACID PRODUCTION BY FERMENTATION</u> .....	33

<u>Chemical Synthesis</u> .....	34
<u>Enzymatic Conversion</u> .....	34
<u>REGULATION</u> .....	34
<u>Federal Drug Administration (FDA)</u> .....	34
<u>U.S. Pharmacopoeia (U.S.P)</u> .....	35
<u>TABLE 16 U.S.P VERIFIED AMINO ACID PRODUCTS</u> .....	36
<u>The Bush Administration</u> .....	36
<u>STRUCTURE OF THE INDUSTRY AND ITS COMPETITIVE</u>	
<u>ASPECTS</u> .....	36
<u>TABLE 17 MAJOR AMINO ACID PRODUCERS</u> .....	37
<u>FIGURE 3 SHARE OF GLOBAL AMINO ACIDS MARKET, 2008 (%)</u> .....	38
<u>IMPORTANT STRATEGIES</u> .....	38
<u>MARKET SHARE</u> .....	39
<u>TABLE 18 LEADING PRODUCERS, BY TYPE, OF AMINO ACID</u> .....	39
<u>FIGURE 4 MARKET SHARE OF MAJOR PLAYERS, 2008 (%)</u> .....	40
<u>MARKET FORCES</u> .....	40
<u>MARKET FORCES (CONTINUED)</u> .....	41
<u>CHAPTER THREE: MONOCLONAL THERAPEUTICS AND COMPANION</u>	
<u>DIAGNOSTIC PRODUCTS (BIO016G)</u> .....	42
<u>INTRODUCTION</u> .....	42
<u>STUDY GOALS AND OBJECTIVES</u> .....	42
<u>REASONS FOR DOING THIS STUDY</u> .....	42
<u>SCOPE OF REPORT</u> .....	42
<u>INTENDED AUDIENCE</u> .....	43
<u>METHODOLOGY</u> .....	43
<u>INFORMATION SOURCES</u> .....	43
<u>ABOUT THE AUTHOR</u> .....	43
<u>RELATED BCC WORK CREDENTIALS</u> .....	43
<u>EXECUTIVE SUMMARY</u> .....	44
<u>TABLE 19 WORLDWIDE SALES OF MONOCLONAL THERAPEUTIC</u>	
<u>AND COMPANION DIAGNOSTICS, THROUGH 2012 (\$ BILLIONS)</u> .....	45
<u>FIGURE 5 WORLDWIDE SALES OF MONOCLONAL THERAPEUTIC</u>	
<u>AND COMPANION DIAGNOSTICS, 2005-2012 (\$ BILLIONS)</u> .....	45
<u>MAB GROWTH IN THERAPEUTICS</u> .....	45
<u>Pharma Moves In</u> .....	46
<u>MAB GROWTH IN DIAGNOSTICS</u> .....	46
<u>Key Drivers and Challenges</u> .....	47
<u>Significant Trends</u> .....	48
<u>OVERVIEW</u> .....	48
<u>TABLE 20 BIOPHARMACEUTICAL CATEGORIES</u> .....	49
<u>TABLE 21 MONOCLONAL ANTIBODIES APPROVED FOR DISEASE</u>	
<u>THERAPY*</u> .....	49
<u>TABLE 21 (CONTINUED)</u> .....	50
<u>TABLE 21 (CONTINUED)</u> .....	51

<u>FIGURE 6 COMPOSITION OF COMMERCIALIZED ANTIBODIES BY TYPE, 2007 AND 2012 (%)</u> .....	51
<u>FIGURE 6 (CONTINUED)</u> .....	52
<u>FIGURE 7 ANTIBODY ILLUSTRATED</u> .....	53
<u>MAB TECHNOLOGY: BEGINNINGS AND MOVEMENTS</u> .....	54
<u>TABLE 22 TIMELINE FOR MAB DEVELOPMENT</u> .....	54
<u>Moving Towards Humanization</u> .....	54
<u>ANTIBODY TECHNOLOGY TYPES</u> .....	55
<u>Humanization</u> .....	55
<u>TABLE 23 WORLDWIDE FORECAST OF THERAPEUTIC MONOCLONAL ANTIBODIES, BY TYPE, THROUGH 2012 (\$ BILLIONS)</u> .....	56
<u>Superhumanization</u> .....	56
<u>Smart Technology</u> .....	57
<u>TABLE 24 SMART TECHNOLOGY ROYALTIES BY LICENSEE AND PRODUCT AS A PERCENTAGE OF TOTAL ROYALTY REVENUE: EXAMPLE OF TECHNOLOGY ROYALTY POTENTIAL (%)</u> .....	58
<u>Fully Human Technology</u> .....	58
<u>Phage Display</u> .....	58
<u>Phage Display (Continued)</u> .....	59
<u>Crucell's Per.C6 and Mabstrat</u> .....	60
<u>Transgenic Mice</u> .....	61
<u>TABLE 25 TRANSGENIC TECHNOLOGIES</u> .....	62
<u>TABLE 25 (CONTINUED)</u> .....	63
<u>Emerging Antibody Technology Types</u> .....	64
<u>Fragments</u> .....	64
<u>Single Chain Antibodies</u> .....	64
<u>Bispecific Antibodies</u> .....	65
<u>Conjugation</u> .....	66
<u>TABLE 26 LEADING CONJUGATION TECHNOLOGIES</u> .....	67
<u>TECHNOLOGY RELATED ISSUES AND CHALLENGES</u> .....	68
<u>Optimization</u> .....	68
<u>Adjusting Glycosylation</u> .....	68
<u>TABLE 27 ANTIBODY TECHNOLOGY BEHIND COMMERCIALIZED MABS</u> .....	69
<u>MANUFACTURING</u> .....	70
<u>LEGALITY AND INTELLECTUAL PROPERTY</u> .....	71
<u>Legality and Intellectual Property (Continued)</u> .....	72
<u>TABLE 28 CAT'S PHAGE AND RIBOSOME DISPLAY PATENTS</u> .....	73
<u>PHARMACEUTICAL AND BIOTECHNOLOGY LANDSCAPE</u> .....	73
<u>TABLE 29 PHARMA'S MAB-RELATED ACQUISITIONS</u> .....	74
<u>FIGURE 8 THE SYNERGY OF PHARMA AND BIOTECH</u> .....	75
<u>TABLE 30 GLOBAL SNAPSHOT: BIOTECHNOLOGY INDUSTRY, 2006</u> .....	75

<u>Pharmaceutical and Biotechnology ... (Continued)</u> .....	76
<u>CHAPTER FOUR: ENVIRONMENTAL MARKETS FOR BIOTECHNOLOGY (BIO019B)</u> .....	77
<u>INTRODUCTION</u> .....	77
<u>STUDY GOALS AND OBJECTIVES</u> .....	77
<u>REASONS FOR STUDY AND IMPORTANCE</u> .....	77
<u>INTENDED AUDIENCE</u> .....	77
<u>SCOPE OF REPORT</u> .....	78
<u>INFORMATION SOURCES</u> .....	79
<u>ANALYST CREDENTIALS</u> .....	79
<u>RELATED REPORTS</u> .....	79
<u>SUMMARY</u> .....	80
<u>TABLE 31 U.S. VALUE OF ENVIRONMENTAL BIOTECHNOLOGY PRODUCTS FOR WASTE TREATMENT, THROUGH 2013 (\$ MILLIONS)</u> .....	81
<u>FIGURE 9 MARKET SHARE BY PRODUCT TYPE, 2008 (%)</u> .....	81
<u>SUMMARY (CONTINUED)</u> .....	82
<u>CHAPTER FIVE: PROTEIN DRUGS: GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES (BIO021C)</u> .....	83
<u>INTRODUCTION</u> .....	83
<u>STUDY GOALS AND OBJECTIVES</u> .....	83
<u>REASONS FOR DOING THE STUDY</u> .....	83
<u>SCOPE OF REPORT</u> .....	83
<u>INTENDED AUDIENCE</u> .....	84
<u>INFORMATION SOURCES</u> .....	84
<u>ANALYST CREDENTIALS</u> .....	84
<u>RELATED REPORTS</u> .....	84
<u>SUMMARY</u> .....	85
<u>TABLE 32 GLOBAL MARKET FOR PROTEIN THERAPEUTICS, THROUGH 2013 (\$ MILLIONS)</u> .....	86
<u>FIGURE 10 GLOBAL MARKET FOR PROTEIN THERAPEUTICS, 2007-2013 (\$ MILLIONS)</u> .....	86
<u>CHAPTER SIX: BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS (BIO022E)</u> .....	87
<u>INTRODUCTION</u> .....	87
<u>STUDY BACKGROUND</u> .....	87
<u>STUDY GOAL AND OBJECTIVES</u> .....	87
<u>INTENDED AUDIENCE</u> .....	88
<u>SCOPE OF REPORT</u> .....	88
<u>Scope of Report (Continued)</u> .....	89
<u>METHODOLOGY AND INFORMATION SOURCES</u> .....	90
<u>COMMERCIAL DRUGS</u> .....	90

<u>DEVELOPMENTAL DRUGS</u> .....	90
<u>TABLE 33 FDA APPROVAL PROCESS FOR NEW DRUGS</u> .....	91
<u>ANALYST CREDENTIALS</u> .....	91
<u>RELATED BCC PUBLICATIONS</u> .....	92
<u>SUMMARY</u> .....	92
<u>TABLE 34 GLOBAL FORECAST FOR BOTANICAL* AND PLANT-</u> <u>DERIVED DRUGS, THROUGH 2013 (\$ BILLIONS)</u> .....	93
<u>FIGURE 11 GLOBAL FORECAST FOR BOTANICAL* AND PLANT-</u> <u>DERIVED DRUGS, 2006-2013 (\$ BILLIONS)</u> .....	93
<u>SUMMARY (CONTINUED)</u> .....	94
<u>SUMMARY (CONTINUED)</u> .....	95
<u>OVERVIEW</u> .....	95
<u>BRIEF HISTORY OF PLANT-DERIVED MEDICINES</u> .....	96
<u>TABLE 35 KEY DATES IN BOTANICAL MEDICINE</u> .....	97
<u>TABLE 36 WELL KNOWN PLANT-DERIVED DRUGS</u> .....	98
<u>OPPORTUNITY LIES BEYOND WHAT'S KNOWN</u> .....	98
<u>FIGURE 12 COMPOSITION OF FDA-APPROVED NATURAL-DERIVED</u> <u>COMPOUNDS IN U.S. (2000-2005)* (%)</u> .....	99
<u>KEY DRIVERS</u> .....	100
<u>KEY CHALLENGES</u> .....	100
<u>SIGNS OF INDUSTRY INVESTMENT</u> .....	101
<u>TABLE 37 SWOT ANALYSIS ON BOTANICAL DRUG DEVELOPMENT</u> .....	102
<u>TABLE 38 KEY SIGNS OF INVESTMENT IN BOTANICAL AND</u> <u>OTHER PLANT-DERIVED DRUGS</u> .....	103
<u>TABLE 38 (CONTINUED)</u> .....	104
<u>BOTANICAL DRUGS DEFINED</u> .....	104
<u>Botanical Drugs Defined (Continued)</u> .....	105
<u>UNDERSTANDING THE REGULATORY PROCESS</u> .....	106
<u>TABLE 39 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS</u> <u>MEDICINALLY</u> .....	107
<u>THE FIRST APPROVED BOTANICAL</u> .....	107
<u>The First Approved Botanical (Continued)</u> .....	108
<u>A GROWING PIPELINE</u> .....	109
<u>FIGURE 13 INDS IN THE FDA BY THERAPEUTIC AREA (NUMBER)</u> .....	109
<u>OVERALL PHARMA LANDSCAPE</u> .....	110
<u>OVERALL PHARMA LANDSCAPE (CONTINUED)</u> .....	111
<u>TABLE 40 TOP PHARMA COMPANIES BY REVENUE, 2007 (\$</u> <u>BILLIONS)</u> .....	112
<u>MAJOR CLASSES OF PLANT DRUGS</u> .....	112
<u>Terpenes and Steroids</u> .....	113
<u>Terpenes</u> .....	113
<u>Steroids</u> .....	114
<u>Alkaloids and Glycosides</u> .....	114
<u>Alkaloids</u> .....	114

• <a href="#">Ergot Alkaloids</a> .....	115
• <a href="#">Morphine Alkaloids</a> .....	115
• <a href="#">Vinca Alkaloids</a> .....	115
<a href="#">Glycosides</a> .....	115
• <a href="#">Cardiac Glycosides</a> .....	116
• <a href="#">Anthraglycosides</a> .....	116
<a href="#">Phenols</a> .....	116
<a href="#">E. Cava Algae</a> .....	116
<a href="#">Flavonoids</a> .....	116
• <a href="#">Resveratrol</a> .....	117
<a href="#">Coumarin</a> .....	117
<a href="#">Catechins</a> .....	117
<a href="#">Proanthocyanidins</a> .....	117
<a href="#">INTELLECTUAL PROPERTY</a> .....	118
<a href="#">PRODUCTION</a> .....	119
<a href="#">PRODUCTION (CONTINUED)</a> .....	120
<a href="#">PRODUCTION (CONTINUED)</a> .....	120
<a href="#">MOVING PRODUCTION FORWARD</a> .....	121
<a href="#">ARTEMISININ: A CASE STUDY</a> .....	122
<a href="#">SUPPLY AND LEGAL ISSUES</a> .....	123
<a href="#">TABLE 41 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANT-</a> <a href="#">BASED MEDICINALS</a> .....	124
<a href="#">DRUG DEVELOPMENT AND MANUFACTURE</a> .....	124
<a href="#">Drug Development ... (Continued)</a> .....	125
<a href="#">TABLE 42 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES</a> .....	126
<a href="#">CHAPTER SEVEN: STEM CELL TECHNOLOGY: CURRENT</a> <a href="#">APPLICATIONS AND FUTURE DIRECTIONS (BIO035C)</a> .....	127
<a href="#">INTRODUCTION</a> .....	127
<a href="#">STUDY GOALS AND OBJECTIVES</a> .....	127
<a href="#">REASONS FOR DOING THE STUDY</a> .....	127
<a href="#">SCOPE OF REPORT</a> .....	127
<a href="#">INTENDED AUDIENCE</a> .....	128
<a href="#">INFORMATION SOURCES</a> .....	128
<a href="#">ANALYST CREDENTIALS</a> .....	129
<a href="#">RELATED BCC REPORTS</a> .....	129
<a href="#">SUMMARY</a> .....	129
<a href="#">SUMMARY (CONTINUED)</a> .....	130
<a href="#">TABLE 43 U.S. MARKET FOR STEM CELLS IN REGENERATIVE</a> <a href="#">MEDICINE REVENUE, THROUGH 2012 (\$ MILLIONS)</a> .....	131
<a href="#">FIGURE 14 U.S. MARKET FOR STEM CELLS IN REGENERATIVE</a> <a href="#">MEDICINE REVENUE, 2005-2012 (\$ MILLIONS)</a> .....	131
<a href="#">INTRODUCTION TO STEM CELLS TECHNOLOGY IN</a> <a href="#">REGENERATIVE MEDICINE MARKET</a> .....	131

<u>STEM CELLS IN CELLULAR THERAPEUTICS</u> .....	132
<u>Stem Cells in Cellular Therapeutics (Continued)</u> .....	133
<u>Stem Cells in Cellular Therapeutics (Continued)</u> .....	134
<u>FIGURE 15 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN CELLULAR THERAPEUTICS</u> .....	135
<u>Stem Cells in Cellular Therapeutics (Continued)</u> .....	136
<u>TABLE 44 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN CELL-BASED THERAPEUTICS FOR HUMAN ADULT AND EMBRYONIC STEM CELLS, THROUGH 2012 (\$ MILLIONS)</u> .....	137
<u>FIGURE 16 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN CELL-BASED THERAPEUTICS FOR HUMAN ADULT AND EMBRYONIC STEM CELLS, 2005-2012 (\$ MILLIONS)</u> .....	138
<u>Stem Cells in Cellular Therapeutics towards Engineering Tissue <i>in Vitro</i> for Transplantation</u> .....	138
<u>Stem Cells in Cellular Therapeutics ... (Continued)</u> .....	139
<u>Stem Cells in Cellular Therapeutics ... (Continued)</u> .....	140
<u>FIGURE 17 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN ENGINEERING TISSUE FOR TRANSPLANTATION THERAPEUTIC STEM CELL BANKING</u> .....	141
<u>FIGURE 18 FLOW DIAGRAM FOR PROCESS OF THERAPEUTIC BANKING OF STEM CELLS</u> .....	142
<u>Therapeutic Stem Cell Banking (Continued)</u> .....	143
<u>TABLE 45 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC STEM CELL BANKING, THROUGH 2012 (\$ MILLIONS)</u> .....	144
<u>FIGURE 19 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC STEM CELL BANKING, 2005-2012 (\$ MILLIONS)</u> .....	144
<u>CHAPTER EIGHT: RNA INTERFERENCE IN THE POST-GENOMIC ERA: MARKETS AND TECHNOLOGIES (BIO062A)</u> .....	145
<u>INTRODUCTION</u> .....	145
<u>STUDY GOALS AND OBJECTIVES</u> .....	145
<u>REASONS FOR DOING THE STUDY</u> .....	145
<u>INTENDED AUDIENCE</u> .....	146
<u>SCOPE OF REPORT</u> .....	146
<u>METHODOLOGY</u> .....	147
<u>INFORMATION SOURCES</u> .....	147
<u>RELATED BCC REPORTS</u> .....	147
<u>ANALYST CREDENTIALS</u> .....	147
<u>SUMMARY</u> .....	148
<u>TABLE 46 GLOBAL VALUE OF RNA INTERFERENCE MARKET BY MARKET SEGMENT, THROUGH 2013 (\$ MILLIONS)</u> .....	149
<u>FIGURE 20 GLOBAL VALUE OF RNA INTERFERENCE MARKET BY MARKET SEGMENT, 2006-2013 (\$ MILLIONS)</u> .....	150
<u>OVERVIEW</u> .....	152
<u>INTRODUCTION</u> .....	152

<u>CONVERGENCE OF POST GENOME TECHNOLOGIES</u> .....	152
<u>TABLE 47 POST GENOME ENABLING TOOLS</u> .....	152
<u>TABLE 48 NEW PARADIGM OF RNA INTERFERENCE</u> .....	153
<u>MARKET POTENTIAL OF RNA INTERFERENCE-BASED PRODUCTS</u> .....	154
<u>GLOBAL RNAI MARKET FORECAST</u> .....	154
<u>TABLE 49 GLOBAL VALUE OF RNA INTERFERENCE MARKET BY MARKET SEGMENT, THROUGH 2013 (\$ MILLIONS)</u> .....	154
<u>GLOBAL RNAI RESEARCH TOOLS MARKET</u> .....	154
<u>TABLE 50 GLOBAL VALUE OF RNA INTERFERENCE RESEARCH TOOLS MARKET BY PRODUCT TYPE, THROUGH 2013 (\$ MILLIONS)</u> .....	155
<u>TABLE 51 GLOBAL VALUE OF RNA INTERFERENCE DRUG MARKET, BY CLASS, THROUGH 2013 (\$ MILLIONS)</u> .....	156
<u>GROWTH DRIVING FORCES IN RNA INTERFERENCE MARKETS</u> .....	157
<u>TABLE 52 PRIMARY FORCES DRIVING RNA INTERFERENCE GROWTH</u> .....	157
<u>RNA INTERFERENCE: BUILDING ON ANTISENSE TECHNOLOGIES</u> .....	158
<u>TABLE 53 KEY ANTISENSE CONTRIBUTIONS TO RNA INTERFERENCE</u> .....	159
<u>APPLICATIONS OF RNA INTERFERENCE</u> .....	159
<u>RNA INTERFERENCE AS A GENE KNOCKDOWN TECHNOLOGY</u> .....	160
<u>RNA INTERFERENCE AS A BIOMARKER</u> .....	160
<u>RNA INTERFERENCE IN THERAPEUTICS</u> .....	160
<u>RNA INTERFERENCE IN AGRICULTURE</u> .....	160
<u>THE RNA INTERFERENCE INDUSTRY</u> .....	161
<u>RNA INTERFERENCE TECHNOLOGIES</u> .....	162
<u>INTRODUCTION</u> .....	162
<u>ROLE OF MESSENGER RNA IN PROTEIN PRODUCTION</u> .....	162
<u>FIGURE 21 ROLE OF MESSENGER RNA IN PROTEIN PRODUCTION</u> .....	163
<u>TABLE 54 BASIC STEPS IN PROTEIN PRODUCTION</u> .....	163
<u>Role of Messenger RNA ... (Continued)</u> .....	164

<u>CHAPTER NINE: DNA DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS (BIO063A)</u> .....	165
<u>INTRODUCTION</u> .....	165
<u>STUDY GOALS AND OBJECTIVES</u> .....	165
<u>REASONS FOR DOING THE STUDY</u> .....	165
<u>SCOPE OF REPORT</u> .....	165
<u>INTENDED AUDIENCE</u> .....	166
<u>METHODOLOGY AND INFORMATION SOURCES</u> .....	166
<u>ANALYST CREDENTIALS</u> .....	166
<u>RELATED BCC REPORTS</u> .....	167

<u>SUMMARY</u> .....	167
<u>TABLE 55 GLOBAL MARKET FOR CLINICAL DNA DIAGNOSTICS, BY SEGMENT, THROUGH 2013 (\$ MILLIONS)</u> .....	167
<u>FIGURE 22 GLOBAL MARKET FOR CLINICAL DNA DIAGNOSTICS, BY SEGMENT, 2005-2013 (\$ MILLIONS)</u> .....	168
<u>OVERVIEW</u> .....	168
<u>INTRODUCTION TO GENOMIC DIAGNOSTICS</u> .....	168
<u>INTRODUCTION TO GENOMIC ... (CONTINUED)</u> .....	169
<u>INTRODUCTION TO GENOMIC ... (CONTINUED)</u> .....	170
<u>EXPRESSION PROFILING AND DISEASE</u> .....	171
<u>EXPRESSION PROFILING AND INFECTIOUS DISEASE</u> .....	172
<u>DNA SEQUENCING FOR GENOTYPING AND DIAGNOSIS</u> .....	172
<u>CLINICAL PHARMACOLOGY</u> .....	173
<u>MUTATION DETECTION AND GENOTYPING FOR SPECIFIC GENES</u> .....	173
<u>IDENTIFICATION OF NEW DISEASE GENES</u> .....	174
<u>REGULATORY FACTORS</u> .....	174
<u>SUCCESSES AND LIMITATIONS OF GENETIC TESTING</u> .....	174
<u>REGULATORY POLICIES</u> .....	175
<u>FOOD AND DRUG ADMINISTRATION: NEW GUIDELINES</u> .....	175
<u>Food and Drug Administration: ... (Continued)</u> .....	176
<u>INTERNAL STANDARDS FOR DNA DIAGNOSTICS</u> .....	177
<u>INSURANCE</u> .....	177
<u>Insurance (Continued)</u> .....	178
<u>MARKETING DIRECTLY TO CONSUMERS</u> .....	179
<u>MARKET FOR CLINICAL DNA DIAGNOSTICS, BY PRODUCT</u> .....	179
<u>MARKET FOR CLINICAL DNA (CONTINUED)</u> .....	180
<u>TABLE 56 GLOBAL MARKET FORECAST FOR DNA DIAGNOSTICS PRODUCTS, THROUGH 2013 (\$ MILLIONS)</u> .....	181
<u>FIGURE 23 GLOBAL MARKET FORECAST FOR DNA DIAGNOSTICS PRODUCTS, 2005-2013 (\$ MILLIONS)</u> .....	181
<u>FIGURE 24 GLOBAL DNA DIAGNOSTICS MARKET, BY PRODUCT SHARE, 2008 (%)</u> .....	182
<u>FIGURE 25 GLOBAL DNA DIAGNOSTICS MARKET, BY PRODUCT SHARE, 2013 (%)</u> .....	183
<u>CHAPTER TEN: BIOLOGIC IMAGING REAGENTS: TECHNOLOGIES AND GLOBAL MARKETS (BIO064A)</u> .....	184
<u>INTRODUCTION</u> .....	184
<u>STUDY GOALS AND OBJECTIVES</u> .....	184
<u>REASONS FOR DOING THE STUDY</u> .....	184
<u>INTENDED AUDIENCE</u> .....	185
<u>SCOPE OF REPORT</u> .....	186
<u>METHODOLOGY</u> .....	186
<u>INFORMATION SOURCES</u> .....	186

<u>RELATED BCC REPORTS</u> .....	186
<u>ANALYST CREDENTIALS</u> .....	187
<u>SUMMARY</u> .....	187
<u>TABLE 57 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TYPE, THROUGH 2013 (\$ MILLIONS)</u> .....	188
<u>FIGURE 26 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TYPE, 2006-2013 (\$ MILLIONS)</u> .....	188
<u>SUMMARY (CONTINUED)</u> .....	189
<u>OVERVIEW</u> .....	190
<u>INTRODUCTION</u> .....	190
<u>BIOLOGIC IMAGING TECHNOLOGIES COVERED IN THIS REPORT</u> .....	191
<u>TABLE 58 SCOPE OF THIS REPORT</u> .....	191
<u>MARKET POTENTIAL OF BIOLOGIC REAGENTS PRODUCTS</u> .....	191
<u>TABLE 59 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY, THROUGH 2013 (\$ MILLIONS)</u> .....	192
<u>TABLE 60 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY END USER MARKET, THROUGH 2013 (\$ MILLIONS)</u> .....	193
<u>FORCES DRIVING BIOLOGIC IMAGING REAGENTS INDUSTRY GROWTH</u> .....	194
<u>TABLE 61 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES</u> .....	194
<u>FORCES DRIVING BIOLOGIC ... (CONTINUED)</u> .....	195
<u>LIFE CYCLE STATUS OF BIOLOGIC IMAGING REAGENTS TECHNOLOGIES</u> .....	196
<u>TABLE 62 LIFE CYCLE STAGE OF BIOLOGIC IMAGING REAGENTS</u> .....	196
<u>THE BIOLOGIC IMAGING REAGENTS INDUSTRY</u> .....	197
<u>TABLE 63 BIOLOGIC IMAGING REAGENTS KEY COMPETITORS</u> .....	198
<u>THE BIOLOGIC IMAGING (CONTINUED)</u> .....	199